CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 14, 2015, Pages 1564-1573

  Pivot, Xavier ^a   Manikhas, Alexey ^b   Zurawski, Bogdan ^d   Chmielowska, Ewa ^e   Karaszewska, Boguslawa ^b   Allerton, Rozenn ^f   Chan, Stephen ^g   Fabi, Alessandra ⁱ   Bidoli, Paolo ^j   Gori, Stefania ^k   Ciruelos, Eva ^l   Dank, Magdolna ^m   Hornyak, Lajos ^b   Margolin, Sara ⁿ   Nusch, Arnd ^b   Parikh, Roma ^h   Nagi, Fareha ^h   DeSilvio, Michelle ^o   Santillana, Sergio ^o   Swaby, Ramona F ^o   Semiglazov, Vladimir ^c   more..

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b St Petersburg City Oncology Dispensary ^*  (Germany)

^c N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^d Regional Oncology Centre Bydgoszcz   (Poland)

^e NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^f ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^j SAN GERARDO HOSPITAL   (Italy)

^k SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^l HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^m SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; ERBB2 PROTEIN, HUMAN; FLUOROURACIL; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CANCER STAGING; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; RISK; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84933556321     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.1794     Document Type: Article

References (35)

1. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
3. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
4. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
5. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005
6. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533-543, 2008
7. Blackwell KL, Pegram MD, Tan-Chiu E, et al: Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 20:1026-1031, 2009
8. Bendell JC, Domchek SM, Burstein HJ, et al: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972-2977, 2003
9. Clayton AJ, Danson S, Jolly S, et al: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639-643, 2004
10. Stemmler HJ, Kahlert S, Siekiera W, et al: Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 15:219-225, 2006
11. Yau T, Swanton C, Chua S, et al: Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol 45:196-201, 2006
12. Pestalozzi BC, Brignoli S: Trastuzumab in CSF. J Clin Oncol 18:2349-2351, 2000
13. Grossi PM, Ochiai H, Archer GE, et al: Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 9:5514-5520, 2003
14. Gabos Z, Sinha R, Hanson J, et al: Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658-5663, 2006
15. Bachelot T, Romieu G, Campone M, et al: Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol 14:64-71, 2013
16. Lin NU, Diéras V, Paul D, et al: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452-1459, 2009
17. Metro G, Foglietta J, Russillo M, et al: Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 22:625-630, 2011
18. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
19. von Minckwitz G, du Bois A, Schmidt M, et al: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27: 1999-2006, 2009
20. von Minckwitz G, Schwedler K, Schmidt M, et al: Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 47: 2273-2281, 2011
21. De Berardis G, Sacco M, Evangelista V, et al: Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): Design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8:21, 2007
22. Cardoso F, Harbeck N, Fallowfield L, et al: Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23:vii11-vii19, 2012 (suppl 7)
23. Cardoso F, Costa A, Norton L, et al: 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21:242-252, 2012
24. Zelen M: The randomization and stratification of patients to clinical trials. J Chronic Dis 27:365-375, 1974
25. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
26. Pivot X, Hackmann J, Manikhas A, et al: Incidence rate of asymptomatic brain metastases in patients with HER2+ metastatic breast cancer screened for EGF111438/CEREBEL study. Cancer Res 71:P4-17-03, 2011 (suppl 24)
27. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
28. Berry G, Kitchin RM, Mock PA: A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med 10:749-755, 1991
29. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
30. Wang R, Lagakos SW, Ware JH, et al: Statistics in medicine: Reporting of subgroup analyses in clinical trials. N Engl J Med 357:2189-2194, 2007
31. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
32. Gelmon K, Boyle F, Kaufman B, et al: Open-label phase III randomized controlled trial comparing taxane-based chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 30, 2012 (suppl 15; abstr LBA671)
33. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
34. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
35. Crown JP, Moulton, B, O'Donovan N: A phase III randomized study of paclitaxel and trastuzumab versus paclitaxel, trastuzumab and lapatinib in first line treatment of HER2 positive metastatic breast cancer. Cancer Res 72:OT1-1-06, 2012 (suppl 3)